Mutation analysis of RASK and the 'FLR exon' of NF1 in sporadic ovarian carcinoma.
Frequent loss of heterozygosity has been described on several chromosomes in ovarian carcinoma (OC), but few tumour suppressor genes (TSGs) have been analysed. Mutations in the GTPase-related domain (GRD) of the TSG NF1 have been described in tumours not usually associated with neurofibromatosis type 1 (NF1). We analysed 36 OCs for mutations in this domain using single-strand conformation polymorphism. The NF1-GRD can downregulate the active form of p21RAS and, therefore, we analysed the same tumours for mutations in RASK. No cases of mutations in NF1-GRD were seen, and only two cases of RASK mutations were found. Thus, activation of the RAS signalling pathway by RASK or NF1 mutations does not appear to be common in OC.
Human Immunogenetics Laboratory, Imperial Cancer Research Fund, London, U.K.
W D
WD
Foulkes
P
P
Englefield
I G
IG
Campbell
D002288:Adenocarcinoma, Mucinous / Q000235:genetics; D001483:Base Sequence; D004252:DNA Mutational Analysis; D004273:DNA, Neoplasm / Q000032:analysis; D005091:Exons; D005260:Female; D020558:GTP Phosphohydrolases / Q000235:genetics; D015972:Gene Expression Regulation, Neoplastic; D016514:Genes, Neurofibromatosis 1; D011905:Genes, ras; D006801:Humans; D008969:Molecular Sequence Data; D010051:Ovarian Neoplasms / Q000235:genetics*; D016133:Polymerase Chain Reaction; D015398:Signal Transduction
D004273:DNA, Neoplasm; D020558:GTP Phosphohydrolases